Aurora Cannabis vs Curaleaf – hostile bid outcome

What happened

Curaleaf Holdings approved a new compensation structure for its Chairman and CEO on October 6, 2026, raising his target 2027 short-term incentive from 125% to 200% of his base salary 2. The board also established a $1 million discretionary target bonus for the Chairman, which is tied to strategic targets and scheduled for evaluation in March 2028 2. Alongside these cash incentives, the company granted the Chairman 1,344,275 time-based restricted stock units with a grant date fair value of $15,448,435 2. These units are set to vest in full on January 5, 2028 2.

On the same day as these compensation adjustments, Curaleaf issued an updated offering circular to Aurora Cannabis shareholders 2. The revised terms propose a consideration of 0.3463 Curaleaf shares plus US$0.75 in cash per Aurora share, which Curaleaf states implies an offer price of US$4.00 2. This represents a 45% premium to Aurora’s 30-day volume-weighted average price as of August 10, 2026 2. Curaleaf clarified in an SEC filing that the press release regarding this circular is furnished rather than filed, meaning it is not subject to Section 18 of the Exchange Act liability 2.

Why it matters

The executive compensation increases align leadership incentives with the execution of "strategic targets" during a period of aggressive expansion 2. Curaleaf’s pursuit of Aurora is built on a projection of creating a global entity with more than US$1.5 billion in last-twelve-month revenue and approximately US$350 million in adjusted EBITDA 2. The company expects the combination to generate at least US$40 million in annual cost synergies 2.

For Aurora shareholders, the offer presents a 110% premium on an ex-cash basis compared to the August 10 unaffected price 2. Curaleaf’s filing contrasts its own cash generation and recent inclusion in the FTSE Canada All Cap Index—effective September 18, 2026—against Aurora’s reliance on equity issuance and declining adjusted EBITDA 2. However, the Aurora board’s refusal to grant due diligence access remains a primary hurdle to the transaction 2. Aurora’s current market capitalization stands at $248.4 million with a share price of $4.01 1.

What's next

Aurora shareholders have until December 1, 2026, to tender their shares into the Curaleaf offer 2. Curaleaf is scheduled to report its third-quarter 2026 financial and operating results after the market close on November 3, 2026, followed by a conference call at 5:00 p.m. ET 2. The determination of the Chairman’s $1 million discretionary bonus will be settled by the Board and Compensation Committee in March 2028 2. The full vesting of the $15.4 million in restricted stock units is scheduled for January 5, 2028 2.

What happened — the development in detail

Chief Administrative Law Judge Derek Julius stayed the Drug Enforcement Administration (DEA) rescheduling hearing on September 29, 2026, to allow for briefing on a Government Accountability Office (GAO) report regarding scheduling procedures 1. This pause follows the GAO’s September 23 publication of report GAO-26-108623, which examines how the DEA handles the classification of controlled substances 1. The DEA was required to file its response to these findings by October 13, 2026 1.

The administrative delay occurs while the broader rule-making process to move medical cannabis out of Schedule I remains unfinished, following a hearing that ran from June 29 to July 14, 2026 1. Although the wider process is stalled, a path for U.S. operators to list on major exchanges was established by an April 22, 2026, order from Acting Attorney General Todd Blanche 1. That order moved cannabis under state medical licenses and FDA-approved cannabis drugs to Schedule III, allowing commercial operators to seek DEA registration for the first time 1. Under these rules, U.S. "plant-touching" firms must bifurcate their operations and wall off their medical business to qualify for blue-chip listings, as adult-use cannabis remains under Schedule I 1.

Trulieve Cannabis Corp became the first U.S. operator to utilize this path, listing on the New York Stock Exchange (NYSE) on June 10, 2026 1. Glass House Brands followed on June 30, 2026, after executing a similar separation of its medical and recreational arms 1. As of October 2026, at least 12 cannabis producers and operators trade on the NYSE or NASDAQ, including Tilray, Cronos, and Canopy Growth 1.

Why it matters

The stay in the DEA proceedings impacts the timeline for U.S. cannabis operators seeking to meet federal compliance standards for major exchange listings 1. Before the April 22 order, operators were locked out of the NYSE and NASDAQ because they could not accurately state they complied with federal law while medical cannabis remained in Schedule I 1. While Trulieve and Glass House Brands successfully listed, their stock performance has been volatile; Glass House Brands closed at $4.26 on October 9, 2026, representing a 68% decline from its June high of $13.25 1.

Investor sentiment has shifted in response to these regulatory hurdles. In a survey conducted between September 21 and September 29, 2026, 67% of respondents believed broader sector uplistings would occur within six months 1. However, because this survey closed the day before the Chief Administrative Law Judge stayed the rescheduling process, analysts at ATB Cormark Capital Markets suggest these probability figures are now likely too high 1. ATB has subsequently moved its base case for full rescheduling to the first quarter of 2027 1.

Access to these exchanges is a primary driver for capital; 81.3% of surveyed investors cited full rescheduling as the top factor that would lead them to increase capital in U.S. operators, while 37.5% identified uplistings to the NYSE or NASDAQ as the second most critical factor 1.

What's next

The DEA’s response to the GAO report, due October 13, 2026, will determine when the administrative stay might be lifted to resume the rescheduling process 1. A formal ruling from the Chief Administrative Law Judge would be required to restart the hearings that concluded their initial phase in July 1.

Market participants are monitoring the U.S. midterm elections, as 70.6% of investors surveyed in late September expected rescheduling to be finalized before the vote 1. A wave of further uplistings is expected to follow the completion of the rescheduling process rather than preceding it 1. The expiry of Curaleaf’s offer for Aurora on December 4, 2026, and Curaleaf’s scheduled financial results on November 3, 2026, will provide further data on how major operators are navigating the current regulatory environment.

What happened

Aurora Cannabis (TSX: ACB) expanded its executive team and intensified its defensive posture against Curaleaf Holdings (TSX: CURA) during September 2026. On September 9, 2026, Aurora appointed a biopharmaceutical executive to lead the commercial acceleration of its global medical cannabis business 2. This appointment follows the company’s August 10, 2026, shareholder meeting where CEO Miguel Martin and Chairman Michael Singer received 85.12% and 86.34% approval ratings, respectively 1.

The regulatory conflict escalated on September 14, 2026, when Aurora issued a formal refutation of Curaleaf’s recent communications 2. Aurora leadership claimed Curaleaf is attempting to "distract shareholders from the facts" regarding the hostile bid 2. This follows Aurora’s September 2, 2026, formal recommendation that shareholders reject the offer, which the board characterized as "inadequate" and a risk to "future upside" 2.

What changed vs. the baseline

The baseline established on September 3, 2026, centered on the initial rejection of Curaleaf’s unsolicited bid. The following changes have occurred since that date:

• Executive Leadership: Aurora added a new biopharmaceutical lead on September 9, 2026, a role not present in the baseline 2.
• Communication Strategy: While the baseline noted a general rejection of the bid, the September 14, 2026, filing represents a specific shift toward accusing Curaleaf of using "distraction" tactics 2.
• Governance Documentation: It is not new that Aurora shareholders support current leadership; the 8-K filing confirming the August 10 voting results was already reflected in the baseline context, though the formal SEC incorporation of these results into registration statements F-10 and S-8 was finalized during this period 1.
• Curaleaf Activity: Curaleaf has released 53 regulatory filings in 2026 to date, covering annual reports and ad-hoc disclosures, though specific new filings regarding the bid price have not been updated since the baseline's reported 45% premium 3.

Why it matters

The appointment of a biopharmaceutical executive suggests Aurora is pivoting toward a medical-heavy defense strategy to justify its "future upside" claims and independent valuation 2. By strengthening its medical cannabis leadership, Aurora is signaling to the market that its specialized pharmaceutical path offers higher long-term value than Curaleaf’s broader retail-focused acquisition 2.

The repeated filings and refutations indicate a protracted hostile takeover battle rather than a quick settlement. Aurora’s move to incorporate shareholder voting results into its F-10 and S-8 registration statements ensures that its current governance structure—which overwhelmingly supports the board’s anti-takeover stance—is legally tethered to its ability to raise capital and issue equity 1.

Open questions

• White Knight Intervention: Despite Aurora’s claims that the bid undervalues the company, no alternative "white knight" bidder has emerged in the filings as of September 22, 2026 23.
• Curaleaf’s Next Move: It remains unclear if Curaleaf will increase its offer price or move to a proxy battle to unseat the board members who were just re-elected with high margins in August 12.
• Regulatory Review: The TSX has not yet issued a public determination regarding the "competing circulars" mentioned in the baseline, leaving the timeline for a final shareholder vote on the Curaleaf offer unconfirmed 3.

What happened — the developments in detail

Aurora Cannabis (TSX: ACB) filed a formal response on September 14, 2026, to a regulatory application by Curaleaf Holdings (TSX: CURA) that sought to halt Aurora’s at-the-market (ATM) program 2. Aurora characterized the filing as a distraction from Curaleaf’s hostile bid, which Aurora claims undervalues the company 2. In its defense, Aurora cited Curaleaf’s own financial position, noting Curaleaf carries more than $1 billion in debt, including $500 million in senior secured notes at an 11.5% interest rate as of June 30, 2026 2. Aurora also confirmed it filed a complaint with the Alberta Securities Commission on September 2, 2026, alleging "unresolved regulatory deficiencies" in Curaleaf’s bid 2.

On September 16, 2026, Aurora announced the acquisition of Safari Flower Company 3. The facility received EU-GMP certification in July 2026 and is expected to provide incremental revenue and adjusted EBITDA 3. This follows other recent international moves, including the acquisition of Internode Pharma and HAP Pharma Limited to expand UK market share 3.

Financially, Aurora reaffirmed its fiscal year 2027 Q2 guidance for sequential growth in net revenue and adjusted EBITDA 3. As of June 30, 2026, Aurora reported a cash balance of $149 million and stated it remains debt-free 3. The company clarified that its ATM program, established in February 2026, has been inactive for several weeks and was not created as a defensive measure against the hostile bid 2.

What changed vs. the baseline

The primary shift since the September 3 baseline is the escalation of regulatory and legal maneuvers between the two firms.

• Regulatory Conflict: While the baseline noted a rejection of the bid, the situation has moved to formal securities commission intervention. Aurora’s September 2 complaint to the Alberta Securities Commission and Curaleaf’s attempt to halt Aurora’s ATM program are new developments since the baseline 2.
• Asset Expansion: The acquisition of Safari Flower Company and the UK-based Internode Pharma and HAP Pharma Limited were not part of the baseline state 3.
• Board Composition: It is not new that Theresa Firestone is off the board; she resigned effective August 31, 2025, following the 2025 Annual General Meeting 1. The baseline mention of the August 10, 2026, AGM confirms the current leadership (Martin and Singer) remains in place, but Firestone's departure dates back one year prior to current events 1.
• Financial Standing: Aurora’s debt-free status and $149 million cash position (as of June 30, 2026) are now being used as a specific rhetorical contrast to Curaleaf’s $1 billion debt load 23.

Why it matters

The conflict has moved beyond a simple price dispute into a battle over capital structures and regulatory standing. Aurora is leveraging its "debt-free" balance sheet to frame Curaleaf’s bid as a risk to Aurora shareholders, suggesting the acquisition is an attempt by Curaleaf to acquire Aurora’s cash and EU-GMP assets to offset its own $1 billion debt 2.

For investors, the reaffirmed Q2 2027 guidance and the Safari Flower Company acquisition suggest Aurora is attempting to prove standalone viability to justify rejecting the 45% premium offered by Curaleaf 23. The focus on EU-GMP certified production in Germany and Poland indicates that Aurora views its international medical cannabis infrastructure as its primary defense against a low-ball offer 3.

Open questions

• ASC Ruling: The outcome of Aurora’s September 2 complaint to the Alberta Securities Commission regarding "bid deficiencies" remains unknown 2.
• ATM Program: While Aurora claims the ATM program is currently inactive, it reserved the right to use it if the Board deems it in the company's best interest, leaving the door open for potential dilution that Curaleaf is actively trying to block 2.
• White Knight: There is currently no mention in the filings of a "white knight" or alternative bidder, leaving shareholders to choose between Curaleaf’s offer or Aurora’s standalone international growth strategy 2.
• Curaleaf Response: Curaleaf has not yet publicly addressed the specific allegations regarding its $1 billion debt load or the interest rate risks cited by Aurora in the September 14 filing 2.

What happened

Curaleaf Holdings filed an application with the Alberta Securities Commission on September 14, 2026, to halt Aurora Cannabis’s at-the-market (ATM) equity program 1. Curaleaf argues the program should be suspended while its hostile takeover bid remains active to prevent Aurora from issuing new shares 1. Aurora issued a response the same day, characterizing the application as an attempt to distract shareholders from the facts of the offer 1.

Following Aurora’s formal rejection of the bid on September 2, Curaleaf escalated its communications:

• September 8: Curaleaf issued a fact sheet to address what it described as "misleading statements" from Aurora leadership 1.
• September 15: Curaleaf sent a direct letter to Aurora shareholders 1.
• September 16: Curaleaf filed a Business Combination Disclosure (Form 425) and an 8-K containing an investor presentation 3.

Outside of the takeover conflict, Curaleaf expanded its retail footprint. On September 16, 2026, the company opened new dispensaries in Philadelphia (Fishtown) and Port Richey, Florida 1. It also relocated a dispensary from Hartford to Meriden, Connecticut, on the same date 1. Earlier in the month, Curaleaf opened a location in Riverview, Florida, on September 4 1.

What changed vs. the baseline

The conflict has moved from a dispute over valuation to a regulatory battle over Aurora's capital structure.

• Regulatory Intervention: The September 14 application to the Alberta Securities Commission is a new development 1. At the September 3 baseline, the focus was on competing circulars; now, Curaleaf is actively seeking to freeze Aurora's ability to raise equity 13.
• Communication Frequency: Curaleaf has increased its filing cadence, submitting four Form 425 disclosures between September 8 and September 16 to counter Aurora's defense 3.
• Retail Footprint: Curaleaf’s expansion is ongoing but not new in strategy. The openings in Philadelphia, Port Richey, and Riverview follow the baseline's noted expansions in Boston and Florida 1.
• Financial Position: Curaleaf’s $500 million senior secured notes offering, which closed in February 2026, remains the foundation for its current liquidity, providing the capital used for these growth initiatives and the pending offer 2.

Why it matters

The application to the Alberta Securities Commission signals a shift toward aggressive legal and regulatory maneuvering. If successful, halting the ATM program would prevent Aurora from diluting Curaleaf’s potential stake or raising defensive capital during the tender period.

Curaleaf’s repeated filings of "Business Combination Disclosures" (Form 425) suggest a high-intensity proxy battle aimed at swaying Aurora’s retail and institutional base before the offer expires 3. The continued opening of dispensaries in Florida and Pennsylvania indicates that Curaleaf is maintaining its standard operations and cash-flow growth despite the significant legal and administrative costs associated with a hostile TSX takeover 1.

Open questions

• ASC Ruling: The Alberta Securities Commission has not yet ruled on the application to halt Aurora’s ATM program 1.
• White Knight Intervention: While the baseline noted the potential for a third-party bidder, no alternative offers for Aurora have been disclosed in filings as of September 18 13.
• Shareholder Response: It is unclear how many Aurora shareholders have tendered their shares following Curaleaf’s September 15 letter 1.
• TSX Action: The Toronto Stock Exchange has not issued new announcements regarding the status of either company’s listing or the specific mechanics of the hostile bid since the initial circulars 13.